Rapid Micro Biosystems announces unaudited Q4, full-year 2023 revenue

Rapid Micro Biosystems, Inc. announced preliminary unaudited fourth quarter and full year 2023 revenue.

Select fourth quarter 2023 highlights and preliminary unaudited revenue

• Placed six new Growth Direct systems
• Growth Direct platform selected by Samsung Biologics to automate microbiology quality control testing
• Growth Direct systems now placed with 100% of commercially approved CAR-T therapy manufacturers
• Completed nine validations
• Cash, cash equivalents and investments of approximately $95 million as of December 31, 2023; cash runway at least into the second half of 2026

The Company currently expects total revenue of between $6.2 million and $6.4 million in the fourth quarter of 2023, representing growth of approximately 45% compared to the prior-year period.

Preliminary unaudited full year 2023 revenue
The Company currently expects total revenue of between $22.4 million and $22.6 million for the full year of 2023. The Company placed 16 new systems with customers and completed the validation of 18 new customer systems during 2023.

The preliminary financial results ranges described herein have not been audited and are subject to adjustment based on the Company’s completion of year-end financial close processes.

The Company plans to announce complete financial results for the fourth quarter and full year 2023 and host a webcast to discuss those results as well as its 2024 outlook in March.
MB Bureau